HZNP stock: buy or sell?
May 22nd, 2020
Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally.
Should I buy HZNP stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Following a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, 2 buy setups work for Horizon Pharma stock right now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Horizon Pharma stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't detect any rating for HZNP stock for the last 30 days.
HZNP stock analysis
After several days of continuous rises in past weeks, Horizon Pharma rocketed 3.40% to $49.56.
Shares of Horizon Pharma ended on May 22nd at $49.56 after topping to a new all time high ($49.81) and rocketed a superb 3.40%. Since price and SMA200d lines crossed up on April, HZNP climbed $19.94 (67.32%). HZNP shows a strong short term uptrend with several rising tops and rising bottoms. Since its last bottom on April 21st, HZNP climbed unceasignly breaking out to new all time highs.
Horizon Pharma shares skyrocketed 5.29% this week and marked a new all time high at $49.81. This week was the fourth green week in a row.
Late March HZNP price bounced up over the SMA of 40 weeks that acted as support stopping new slides. This week, SMA10w and SMA20w crossed up triggering a rise of 5.29%.
HZNP stock price history
HZNP IPO was on July 28th, 2011 at $9.00 per share1. Since then, HZNP stock surged a 450.70%, with a yearly average of 56.30%. If you had invested $1,000 in HZNP stock in 2011, it would worth $4,507.00 today.
1: Adjusted price after possible price splits or reverse-splits.
HZNP stock historical price chart
HZNP stock reached all-time highs on May/22 with a price of $49.81.
HZNP stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last 30 days we have not detected any price forecast for Horizon Pharma stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareHorizon Pharma presented amazing results for 2018-Q4 . Horizon Pharma skyrocketed Earnings per Share (EPS) by 24.10%, beating experts consensus of $0.54. Horizon Pharma posted $0.67.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Horizon Pharma annual sales skyrocketed an extraordinary 14.33% to $1,207.57 million USD from $1,056.23 marked in 2017. When comparing 2018 vs 2017, in line, profit margin (that is, the net income divided by revenues) rocketed a 31.88% to -6.14%.
|2013||$74 M||-||$-149.01 M-201.3%||-|
|2014||$297 M||301.18%||$-263.60 M-88.8%||76.90%|
|2015||$757 M||154.94%||$40 M5.2%||-115.00%|
|2016||$981 M||29.60%||$-166.83 M-17.0%||-522.02%|
|2017||$1,056 M||7.66%||$-401.59 M-38.0%||140.71%|
|2018||$1,208 M||14.33%||$-74.19 M-6.1%||-81.53%|
Quarterly financial resultsHorizon Pharma posted $355.54 M in sales for 2018-Q4, a 9.29% up compared to previous quarter. Reported quarter earnings marked $89.95 M with a profit margin of 25.30%. Profit margin climbed a 17.30% compared to previous quarter when profit margin was 8.00%. When comparing sales to same quarter last year, Horizon Pharma sales marked a dazzling increase and boosted a 29.66%. Looking back to recent quarterly results, Horizon Pharma posted 3 negative quarters in a row.
|2017-Q1||$221 M||-||$-90.57 M-41.0%||-|
|2017-Q2||$290 M||31.08%||$-209.54 M-72.4%||131.36%|
|2017-Q3||$272 M||-6.17%||$-63.97 M-23.5%||-69.47%|
|2017-Q4||$274 M||0.95%||$-46.45 M-16.9%||-27.39%|
|2018-Q1||$224 M||-18.36%||$-157.33 M-70.3%||238.72%|
|2018-Q2||$303 M||35.27%||$-32.84 M-10.8%||-79.13%|
|2018-Q3||$325 M||7.42%||$26.03 M8.0%||-179.27%|
|2018-Q4||$356 M||9.29%||$89.95 M25.3%||245.55%|
Horizon Pharma ownershipHaving a look at Horizon Pharma ownership structure gives valuable information about the company and its governance (insider ownership) or the amount of investors that are on the short side.
Horizon Pharma shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 1.31% of all shares.
Bearish positions for HZNP stock account 0.00%, no big difference from last month.
For a better understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$9.5 B|
|Total shares||190.8 M|
|Float shares||177.3 M|
|- Institutional holdings (%)||91.7%|
|- Insider holdings (%)||1.3%|
|Shares in short selling||0.0%|
|Friday, May 22nd, 2020|
|Day range||$47.73 - $49.81|
|Average true range||$2.33|
|50d mov avg||$34.88|
|100d mov avg||$35.23|
|200d mov avg||$32.26|
Horizon Pharma performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared Horizon Pharma against in the following table: